Clinical Trials Directory

Trials / Conditions / Locally Advanced or Metastatic NSCLC

Locally Advanced or Metastatic NSCLC

13 registered clinical trials studyying Locally Advanced or Metastatic NSCLC — 3 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metast
NCT07109531
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Phase 3
RecruitingA Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT06461156
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 1
Not Yet RecruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung
NCT05990127
AkesoPhase 3
TerminatedA Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
NCT05662670
Suzhou Junjing BioSciences Co., Ltd.Phase 1 / Phase 2
CompletedDrug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
NCT05631678
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Phase 1
CompletedReal World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
NCT04207775
AstraZeneca—
CompletedAssessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy S
NCT04360915
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Phase 1
Active Not RecruitingASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
NCT04143607
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Phase 3
Active Not RecruitingWhole Genomic Landscape of Advanced EGFR-mutant NSCLC
NCT03969823
Seoul National University HospitalN/A
UnknownPBF-1129 in Patients With NSCLC
NCT03274479
Palobiofarma SLPhase 1
CompletedOsimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
NCT03414814
Seoul National University HospitalPhase 2
UnknownSafety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastati
NCT03502850
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Phase 1 / Phase 2
CompletedAsia PDL1 Study Among NSCLC Patients
NCT03037086
AstraZeneca—